200.77
-0.63%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CSL
Its shares trade on ASX under the ticker CSL.AX. It has been listed since 8 June 1994. In the fiscal year to 30 June 2026, it reported revenue of $16.04bn and a net loss of $2.64bn. At that date it held total assets of $33.63bn and shareholders' equity of $14.79bn.
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria. The company offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Jun 1994
- Employees
- 25,000
- Website
- csl.com ↗
Leadership
Pay as last reported
- Dr. Brian McnameeNon-Executive Independent Chairman of the Board$604,848
- Mr. Paul MckenzieChief Executive Officer, Managing Director, Executive Director, since 2019$8.2m
- Mr. John LevyInterim Chief Financial Officer
- Ms. Roanne ParryChief Human Resource Officer
- Mr. Mark HillExecutive Vice President, Chief Digital Information Officer
- Mr. Greg BossExecutive Vice President, Legal and CSL Group General Counsel$2.5m
- Mr. Ken LimExecutive Vice President, Chief Strategy Officer
- Ms. Joy LintonChief Financial Officer$3.7m
- Dr. William MezzanotteExecutive Vice President, Head Research & Development$2.2m
- Mr. Herve GisserotSenior Vice President, General Manager - CSL Vifor
- Mr. Stephen MarlowSenior Vice President, General Manager - CSL Plasma
- Mr. David RossSenior Vice President, General Manager - CSL Seqirus
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 89
- Environment
- 75
- Social
- 99
- Governance
- 92
- Direct emissions (scope 1)
- 130,000 t
- Energy emissions (scope 2)
- 221,000 t
- Women in the workforce
- 59%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CSL Ltd has a strong portfolio of life-saving products, including vaccines, gene therapies, and plasma-derived therapies. This diverse product range helps to mitigate risks and ensures a consistent revenue stream.
- The company has a major competitive advantage through its strong research and development capabilities. It invests heavily in innovation and clinical trials, resulting in a continuous pipeline of new products and treatments.
Weaknesses
- One of CSL Ltd's weaknesses lies in its geographical concentration of operations. With the majority of its manufacturing facilities located in Australia, the company is exposed to risks associated with regulatory changes, natural disasters, and disruptions in the supply chain.
- Additionally, CSL Ltd heavily relies on plasma for its products. Any significant disruption in the plasma supply chain could impact production and lead to potential shortages.
Opportunities
- The increasing demand for healthcare products and services globally provides CSL Ltd with significant growth opportunities. Expanding into emerging markets with a high demand for quality healthcare can help the company increase its market share and revenue.
- The advancements in gene therapies and biotechnology open doors for CSL Ltd to develop new and innovative treatments. Partnering with academic institutions and biotechnology companies can enable the company to stay at the forefront of cutting-edge research.
Threats
- CSL Ltd faces the threat of increasing competition from both established pharmaceutical companies and emerging biotech startups. This could potentially impact market share and profit margins.
- The changing regulatory landscape, especially in the healthcare industry, also poses a threat to CSL Ltd. Compliance with evolving regulations and the possibility of stricter regulations can increase costs and limit operational flexibility.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.